Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:07:59 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:ALKS - ALKERMES PLC - https://www.alkermes.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ALKS - Q0.128.65·39.240.134.91+1.364.11,938.966,18417,39634.38  35.02  34.1136.45  25.16518:15:35Jan 0615 min RT 2¢

Recent Trades - Last 10 of 17396
Time ETExPriceChangeVolume
18:15:35Q35.4181.86810
16:20:00Q34.911.36343
16:10:04Q34.911.361
16:04:28Q34.911.361
16:04:24Q34.911.361
16:04:13Q34.911.361
16:04:13Q34.911.361
16:04:07Q34.911.361
16:04:02Q34.911.361
16:02:47Q34.911.36144

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-06 07:00U:ALKSNews ReleaseAlixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
2025-12-30 16:00U:ALKSNews ReleaseAlkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-05 16:01U:ALKSNews ReleaseAnnouncement relating to despatch of Rule 15 proposal
2025-11-25 16:00U:ALKSNews ReleaseAlkermes to Participate in Two Upcoming Investor Conferences
2025-11-19 06:00U:ALKSNews ReleaseAlkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
2025-11-17 05:45U:ALKSNews ReleaseAvadel Board of Directors Declares Lundbeck Proposal a "Company Superior Proposal"
2025-11-14 07:45U:ALKSNews ReleaseAlkermes Response to Avadel Announcement
2025-11-14 05:45U:ALKSNews ReleaseAvadel Receives Unsolicited Proposal from Lundbeck
2025-11-12 07:30U:ALKSNews ReleaseAlkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
2025-11-06 16:00U:ALKSNews ReleaseAlkermes to Participate in Two Upcoming Investor Conferences
2025-11-05 09:00U:ALKSNews ReleaseFORM 8.1(a) & (b) (Opening Position Disclosure)
2025-10-28 07:00U:ALKSNews ReleaseAlkermes plc Reports Third Quarter 2025 Financial Results
2025-10-22 07:00U:ALKSNews ReleaseAlkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
2025-10-20 16:00U:ALKSNews ReleaseAlkermes to Report Third Quarter Financial Results on October 28, 2025
2025-09-12 09:00U:ALKSNews ReleaseAlkermes Appoints Joshua Reed as Chief Financial Officer
2025-09-11 07:00U:ALKSNews ReleaseAlkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards(TM) Program
2025-09-08 03:15U:ALKSNews ReleaseAlkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
2025-08-25 07:00U:ALKSNews ReleaseAlkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025
2025-07-29 07:00U:ALKSNews ReleaseAlkermes plc Reports Second Quarter 2025 Financial Results
2025-07-21 06:00U:ALKSNews ReleaseAlkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1